Novartis United States Novartis Patient Assistance Foundation (NPAF) NPAF is an independent 501(c)(3) non-profit organization that provides Novartis medications free of cost to eligible patients who have limited or no prescription insurance coverage and cannot afford the cost of their medication....
Novartis said in a statement at the time, as quoted in The New York Times, that "We recognize that sustainability of health care systems is a complex topic and we welcome the opportunity to be part of the dialogue." "Nothing happened. Drug companies do not want any dialogue or reasonable ...
Patient perspectives Adverse event reporting The STEP program Sickle cell disease (SCD) Program overview Multiple sclerosis (MS) Cancer Application for funding to help address health disparities Health disparities Patient resources Patients and caregivers Healthcare professionals Novartis pipe...
In, EffectivenessSupport, PatientStrategy, MitigationBermangorvine, By Martin
Just as Novartis has delayed an FDA filing in prostate cancer, Exelixis is also awaiting more mature overall survival data for a combination of its Cabometyx and Roche's Tecentriq to submit an application. (Exelixis) Another prostate cancer trial has hit its main goal, and y...
Priority Review designation means the FDA's goal is to take action on an application within six months, compared to 10 months under standard review. About SMA SMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA...
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program—Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries BACKGROUND: The aim of this paper is to explore the application and clinical significance of color Dopp...
Whether you're a patient, job seeker, health or media professional or investor, you can find the best way to contact us from the options below. General Contact General Contact 1 888 NOW NOVA (1 888 669 6682) Monday - Friday, 8:30 AM - 5:00 PM ET. ...
United States Patent Application 20150004191 Kind Code: A1 Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added....